SAN DIEGO–(BUSINESS WIRE)–Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the presentation of new preclinical data for elunetirom, the company’s lead asset currently in Phase 2 clinical development for adjunctive major depressive disorder (MDD) and bipolar depression, at the 64th Annual American College of Neuropsychopharmacology (ACNP) Annual Meeting taking place in Nassau
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
